These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20597679)

  • 21. Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr genes and mutations in gyrA and parC.
    Rodríguez-Martínez JM; Briales A; Velasco C; Díaz de Alba P; Martínez-Martínez L; Pascual A
    J Antimicrob Chemother; 2011 Jun; 66(6):1405-7. PubMed ID: 21427105
    [No Abstract]   [Full Text] [Related]  

  • 22. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
    Li Q; Bi X; Diao Y; Deng X
    Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.
    Sorlozano A; Gutierrez J; Jimenez A; de Dios Luna J; Martínez JL
    J Clin Microbiol; 2007 Aug; 45(8):2740-2. PubMed ID: 17567787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of fluoroquinolone-resistant Escherichia coli strains isolated from urine clinical samples.
    Dehbanipour R; Khanahmad H; Sedighi M; Bialvaei AZ; Faghri J
    J Prev Med Hyg; 2019 Mar; 60(1):E25-E30. PubMed ID: 31041407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of aac(6')-Ib-cr gene associated with double mutations in gyrA and parC in Escherichia coli isolates from patients with urinary tract infections.
    Volcão LM; Lacava JP; Gewehr MF; Leal VL; Ramis IB; Ramos DF; Gonçalves CV; Possuelo LG; Minarini LAR; da Silva PEA; von Groll A
    J Glob Antimicrob Resist; 2018 Jun; 13():180-183. PubMed ID: 29307860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
    Drago L; Nicola L; Mattina R; De Vecchi E
    BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.
    Kivata MW; Mbuchi M; Eyase FL; Bulimo WD; Kyanya CK; Oundo V; Muriithi SW; Andagalu B; Mbinda WM; Soge OO; McClelland RS; Sang W; Mancuso JD
    BMC Microbiol; 2019 Apr; 19(1):76. PubMed ID: 30961546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observation of a new pattern of mutations in
    Dasgupta N; Paul D; Chanda DD; Chetri S; Chakravarty A; Bhattacharjee A
    Indian J Med Microbiol; 2018; 36(1):131-135. PubMed ID: 29735844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran.
    Mirzaii M; Jamshidi S; Zamanzadeh M; Marashifard M; Malek Hosseini SAA; Haeili M; Jahanbin F; Mansouri F; Darban-Sarokhalil D; Khoramrooz SS
    J Glob Antimicrob Resist; 2018 Jun; 13():197-200. PubMed ID: 29747008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C; Tirado-Vélez JM; Calatayud L; Tubau F; Garmendia J; Ardanuy C; Marti S; de la Campa AG; Liñares J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli.
    Han JH; Garrigan C; Johnston B; Nachamkin I; Clabots C; Bilker WB; Santana E; Tolomeo P; Maslow J; Myers J; Carson L; Lautenbach E; Johnson JR;
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):275-280. PubMed ID: 27939288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Supermutators' found amongst highly levofloxacin-resistant E. coli isolates: a rapid protocol for the detection of mutation sites.
    Zayed AA; Essam TM; Hashem AG; El-Tayeb OM
    Emerg Microbes Infect; 2015 Jan; 4(1):e4. PubMed ID: 26038761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
    Patel SN; Melano R; McGeer A; Green K; Low DE
    Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.
    Johnson JR; Tchesnokova V; Johnston B; Clabots C; Roberts PL; Billig M; Riddell K; Rogers P; Qin X; Butler-Wu S; Price LB; Aziz M; Nicolas-Chanoine MH; Debroy C; Robicsek A; Hansen G; Urban C; Platell J; Trott DJ; Zhanel G; Weissman SJ; Cookson BT; Fang FC; Limaye AP; Scholes D; Chattopadhyay S; Hooper DC; Sokurenko EV
    J Infect Dis; 2013 Mar; 207(6):919-28. PubMed ID: 23288927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
    Nakase K; Sakuma Y; Nakaminami H; Noguchi N
    Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
    Nathania I; Nainggolan IM; Yasmon A; Nusatia ACM; Tjoa E; Gunardi WD; Moehario LH
    BMC Microbiol; 2022 Oct; 22(1):250. PubMed ID: 36253712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.